患者参与能否助力临床试验设计与入组?前列腺癌质子与光子治疗比较研究的观察
COMPPARE 研究基于患者参与过程设计为前瞻性平行队列比较,实际入组 2524 例接受 IMRT 或质子治疗的前列腺癌患者,来自 51 家机构,历时 52 个月,其中黑人患者 404 例占 16%,超过 10% 的目标。尽管中心启动中位时间 18 个月(计划 6 个月)且 COVID-19 高峰影响入组,研究仍实现快速且具代表性的入组,提示患者参与过程可有效设计以患者为中心的临床试验。
要点
- COMPPARE 实际入组 2524 例前列腺癌患者,来自 51 家机构,历时 52 个月。
- 黑人患者 404 例,占研究人群 16%,超过 10% 的入组目标。
- 中心启动中位时间 18 个月(计划 6 个月),COVID-19 高峰与入组显著下降相关。
核心结论
- 尽管中心启动和 COVID-19 高峰导致未预期延迟,COMPPARE 大样本快速且具代表性的入组提示患者参与过程可高效设计以患者为中心的临床试验。
研究设计与样本
- 基于患者参与过程,COMPPARE 设计为前瞻性平行队列比较,务实地比较接受质子或光子治疗的前列腺癌患者的结局,目标是快速、具代表性且可比的质子治疗与 IMRT 入组。
主要发现
- 中心启动中位需 18 个月而非计划的 6 个月,COVID-19 高峰与入组显著下降相关。
- 52 个月内从 51 家机构入组 2524 例接受 IMRT 和质子治疗的患者。
- 入组包括 404 例黑人患者,占研究人群 16%,超过 10% 的目标。
临床怎么用
- 在前列腺癌质子与光子比较研究中,可借鉴患者参与过程识别患者偏好以优化研究设计和入组策略。
- 规划多中心比较研究时应考虑中心启动时间可能长于计划,并为 COVID-19 等外部冲击导致的入组下降预留应对。
- 为提升代表性,可设定少数族裔入组目标(如黑人患者 10%)并通过患者参与过程促进达成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Slow accrual has been problematic in many clinical trials, especially comparative studies of proton and photon radiation. In addition to proton facility limitations, issues of patient and institutional preferences may also affect trial accrual. We hypothesized that patient engagement could inform the design of a comparative trial with the potential for rapid and representative accrual. Previously, we detailed a patient engagement process that identified patient preferences for treatment outcomes and study design for a comparative study of proton and photon therapy in prostate cancer (COMPPARE). We tested the efficacy of this engagement process and herein report the resulting design of COMPPARE and its accrual outcomes. METHODS AND MATERIALS: Based on patient engagement, COMPPARE was designed as a large prospective comparison of outcomes between parallel cohorts of prostate cancer patients treated pragmatically with protons or photons, with the goal of rapid, representative, and comparable proton therapy and intensity modulated radiation therapy accrual. RESULTS: Site activation required a median of 18 months rather than the planned 6 months, and COVID-19 surges were associated with significant accrual depressions. However, 2524 patients treated with intensity modulated radiation therapy and proton therapy from 51 institutions were accrued in 52 months to COMPPARE, including 404 Black patients, comprising 16% of the study population, exceeding the goal of 10%. CONCLUSIONS: Despite unanticipated delays due to site activation and COVID-19 surges, rapid and representative accrual of the large COMPPARE cohorts suggests that a patient engagement process can be highly effective in designing a patient-centric clinical trial.
引用
- Mendenhall NP, Bryant CM, Katz AJ, et al. Can Engagement Aid in Design and Accrual on Clinical Trials? Observations from Comparative Study of Proton and Photon Therapy in Prostate Cancer: A Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42526648. doi:10.1016/j.ijrobp.2026.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。